Patent Litigations

1. List of Calquence drug patents

CALQUENCE litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US10272083 February, 2023 Petition Filed Sandoz Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: 2021-10-31

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily

Dosage: TABLET;ORAL

More Information on Dosage

CALQUENCE family patents

12

United States

3

Taiwan, Province of China

3

IB

2

Argentina

1

Korea, Republic of

1

Australia

1

EA

1

Canada

1

Japan

1

China

1

European Union

2. List of Calquence drug patents

CALQUENCE litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US10272083 February, 2023 Petition Filed Sandoz Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 21, 2026

Drugs and Companies using ACALABRUTINIB ingredient

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab

Dosage: CAPSULE;ORAL

How can I launch a generic of CALQUENCE before it's patent expiration?
More Information on Dosage

CALQUENCE family patents

12

United States

3

Taiwan, Province of China

3

IB

2

Argentina

1

Korea, Republic of

1

Australia

1

EA

1

Canada

1

Japan

1

China

1

European Union

3. List of Mavenclad drug patents

MAVENCLAD's oppositions filed in EPO

MAVENCLAD litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US7713947 January, 2023 Petition Filed Hopewell Pharma Ventures, Inc. et al.
US8377903 January, 2023 Petition Filed Hopewell Pharma Ventures, Inc. et al.
US7713947 October, 2022 PO preliminary response filed Merck Serono SA TWi Pharmaceuticals, Inc.
US8377903 October, 2022 Submitted Merck Serono SA TWi Pharmaceuticals, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377903 EMD SERONO INC Cladribine regimen for treating multiple sclerosis
May, 2026

(3 years from now)

US7713947 EMD SERONO INC Cladribine regimen for treating multiple sclerosis
Oct, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 29, 2022

Drugs and Companies using CLADRIBINE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Treating rrms or spms with oral cladribine: (i) 2-4 months induction with 1.7 mg/kg - 3.5 mg/kg cladribine; (ii) cladribine-free period of about 8-10 months; (iii) 2-4 months maintenance with about 1.7 mg/kg cladribine; (iv) cladribine-free period; Treating ms with oral cladribine acc. to the steps (i) induction period with about 1.7 mg/kg-3.5 mg/kg cladribine; (iii) maintenance period with about 1.7 mg/kg cladribine

Dosage: TABLET;ORAL

How can I launch a generic of MAVENCLAD before it's patent expiration?
More Information on Dosage

MAVENCLAD family patents

8

European Union

7

Japan

5

Spain

4

United States

3

Portugal

3

Lithuania

3

Slovenia

3

Hungary

3

Poland

3

Denmark

2

Argentina

2

Canada

2

Cyprus

2

Australia

1

Singapore

1

Brazil

1

Croatia

1

Norway

1

Austria

1

Mexico

1

China

1

Korea, Republic of

1

EA

1

South Africa

1

Luxembourg

1

ME

1

Ukraine

1

Israel

1

RS

4. List of Venclexta drug patents

VENCLEXTA litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US11110087 October, 2022 PO preliminary response filed Genentech, Inc. et al. Dr. Reddy's Laboratories, Inc. et al.
US10993942 February, 2022 Trial Instituted Genentech, Inc. et al. Dr. Reddy's Laboratories, Inc. et al.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10993942 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(10 years from now)

US11110087 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 15, 2026
M (M) Oct 16, 2023

Drugs and Companies using VENETOCLAX ingredient

Market Authorisation Date: 11 April, 2016

Treatment: Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for 1 week followed by 100 mg per day for 1 week; Treatment of acute myeloid leukemia (aml) by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine in adults 75 years or older or having certain comorbidities according to a dose ramp-up including a 100 mg per day dose; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose

Dosage: TABLET;ORAL

How can I launch a generic of VENCLEXTA before it's patent expiration?
More Information on Dosage

VENCLEXTA family patents

10

United States

4

Japan

3

China

2

Korea, Republic of

2

European Union

1

Hong Kong

1

New Zealand

1

Russia

1

Canada

1

Mexico

5. List of Trulance drug patents

TRULANCE's oppositions filed in EPO

TRULANCE litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US7041786 October, 2022 Instituted Salix Pharmaceuticals, Inc. MSN Laboratories Private Ltd.
US9610321 June, 2022 Institution Denied Bausch Health Ireland Limited et al. Mylan Pharmaceuticals Inc. et al.
US9616097 June, 2022 Institution Denied Bausch Health Ireland Limited et al. Mylan Pharmaceuticals Inc. et al.
US9919024 June, 2022 Terminated-Denied Bausch Health Ireland Limited Mylan Pharmaceuticals Inc.
US9925231 June, 2022 Institution Denied Bausch Health Ireland Limited et al. Mylan Pharmaceuticals Inc. et al.
US7041786 March, 2022 Trial Instituted Bausch Health Ireland Limited et al. Mylan Pharmaceuticals Inc. et al.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7041786 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jan, 2028

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616097 SALIX Formulations of guanylate cyclase C agonists and methods of use
Aug, 2032

(9 years from now)

US9610321 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

US9919024 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

US9925231 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 19, 2022

Drugs and Companies using PLECANATIDE ingredient

NCE-1 date: 2021-01-19

Market Authorisation Date: 19 January, 2017

Treatment: Chronic idiopathic constipation; Irritable bowel syndrome with constipation

Dosage: TABLET;ORAL

How can I launch a generic of TRULANCE before it's patent expiration?
More Information on Dosage

TRULANCE family patents

27

United States

8

Japan

7

European Union

5

Australia

5

Canada

5

China

4

Hong Kong

4

Spain

2

EA

1

Portugal

1

Germany

1

Denmark

1

Cyprus

6. List of Xarelto drug patents

XARELTO's oppositions filed in EPO

XARELTO litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US10828310 September, 2022 Instituted Bayer Pharma AG Teva Pharmaceuticals USA, Inc
US10828310 September, 2022 Instituted Bayer Pharma AG InvaGen Pharmaceuticals, Inc.
US10828310 February, 2022 Trial Instituted Bayer Pharma AG et al. Mylan Pharmaceuticals Inc. et al.
US9539218 May, 2018 Terminated-Denied Bayer Intellectual Property GmbH Mylan Pharmaceuticals Inc.
US7157456 October, 2016 Terminated-Dismissed Bayer Intellectual Property GmbH Mylan Pharmaceuticals Inc
US9539218 January, 2014 Decision Frank Misselwitz et al
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7157456 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Aug, 2024

(1 year, 5 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539218 JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Feb, 2034

(10 years from now)

US10828310 JANSSEN PHARMS Reducing the risk of cardiovascular events
Jan, 2039

(15 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Aug 23, 2024
M (M) Mar 10, 2023
Pediatric Exclusivity (PED) Apr 11, 2023

Drugs and Companies using RIVAROXABAN ingredient

Market Authorisation Date: 01 July, 2011

Treatment: Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days; Treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days; Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days; Reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days; Prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding with once daily, rapid-release tablet administered for at least 5 consecutive days; Treatment of dvt and/or pe and reduction in the risk of recurrent dvt and/or pe in pediatric patients (>=50 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; After completion of initial treatment lasting at least 6 months, to reduce the risk of recurrence of deep vein thrombosis and/or pulmonary embolism in certain patients with once daily, rapid-release tablet administered for at least 5 consecutive days; Prophylaxis of pe, dvt and/or stroke in pediatric patients (>=50 kg) aged 2 years and older with congenital heart disease after fontan procedure with once daily, rapid-release tablet administered for at least 5 consecutive days; Treatment of dvt and/or pe and reduction in risk of recurrent dvt and/or pe in pediatric patients (30-49.9 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; Reduction of risk of cardiovascular death, myocardial infarction, and stroke in patients with cad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily; Reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily

Dosage: TABLET;ORAL

How can I launch a generic of XARELTO before it's patent expiration?
More Information on Dosage

XARELTO family patents

12

United States

6

European Union

5

Norway

4

China

4

Korea, Republic of

3

Portugal

3

Germany

3

Spain

3

Croatia

3

New Zealand

3

Argentina

3

Taiwan, Province of China

3

Hong Kong

3

Japan

3

Slovenia

3

Poland

3

Australia

3

Denmark

2

Turkey

2

Singapore

2

Brazil

2

Dominican Republic

2

Mexico

2

Morocco

2

South Africa

2

Canada

2

Cyprus

2

Hungary

2

Ukraine

2

Cuba

1

El Salvador

1

Malaysia

1

Uruguay

1

Russia

1

Guatemala

1

Colombia

1

Estonia

1

Austria

1

Peru

1

Belgium

1

Honduras

1

Slovakia

1

Lithuania

1

Luxembourg

1

Czech Republic

1

Israel

1

Bulgaria

1

Netherlands

7. List of Idhifa drug patents

IDHIFA litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US10610125 August, 2022 Terminated-Settled Servier Pharmaceuticals LLC et al. Rigel Pharmaceuticals, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125 CELGENE CORP Methods and compositions for cell-proliferation-related disorders
Jun, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 1, 2024

Drugs and Companies using ENASIDENIB MESYLATE ingredient

Market Authorisation Date: 01 August, 2017

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

More Information on Dosage

IDHIFA family patents

15

United States

3

Japan

2

Australia

2

China

1

Canada

1

Mexico

1

Spain

1

European Union

8. List of Tibsovo drug patents

TIBSOVO litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US10610125 August, 2022 Terminated-Settled Servier Pharmaceuticals LLC et al. Rigel Pharmaceuticals, Inc.
Can you believe TIBSOVO received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125 SERVIER Methods and compositions for cell-proliferation-related disorders
Jun, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2023
Orphan Drug Exclusivity (ODE) Aug 25, 2028
New Indication (I) May 25, 2025

Drugs and Companies using IVOSIDENIB ingredient

NCE-1 date: 2022-07-20

Market Authorisation Date: 20 July, 2018

Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml) and where the mutant idh1 has the ability to convert alpha-ketoglutarate into 2-hydroxyglutarate (2-hg); A method of treating a cancer characterized by an idh1 mutation where the cancer is newly diagnosed acute myeloid leukemia (aml) and where the mutant idh1 has the ability to convert alpha-ketoglutarate into 2-hydroxyglutarate (2-hg)

Dosage: TABLET;ORAL

How can I launch a generic of TIBSOVO before it's patent expiration?
More Information on Dosage

TIBSOVO family patents

15

United States

3

Japan

2

Australia

2

China

1

Canada

1

Mexico

1

Spain

1

European Union

9. List of Ozempic drug patents

OZEMPIC's oppositions filed in EPO

OZEMPIC litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US8114833 March, 2022 Terminated-Settled Novo Nordisk A/S Fresenius Kabi USA, LLC
US8114833 July, 2020 Terminated-Settled Novo Nordisk A/S Pfizer Inc.
US8114833 December, 2019 Terminated-Settled Novo Nordisk A/S Pfizer Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Jan 16, 2023
New Dosing Schedule (D) Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of OZEMPIC before it's patent expiration?
More Information on Dosage

OZEMPIC family patents

6

United States

4

China

4

Denmark

3

European Union

2

Portugal

2

Spain

2

Japan

2

Hungary

2

Slovenia

2

Poland

1

Turkey

1

Russia

1

Brazil

1

Mexico

1

Korea, Republic of

1

Hong Kong

1

Canada

1

Cyprus

1

Australia

10. List of Saxenda drug patents

SAXENDA's oppositions filed in EPO

SAXENDA litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US8114833 March, 2022 Terminated-Settled Novo Nordisk A/S Fresenius Kabi USA, LLC
US8114833 July, 2020 Terminated-Settled Novo Nordisk A/S Pfizer Inc.
US8114833 December, 2019 Terminated-Settled Novo Nordisk A/S Pfizer Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Dec 4, 2023

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 23 December, 2014

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of SAXENDA before it's patent expiration?
More Information on Dosage

SAXENDA family patents

6

United States

4

China

4

Denmark

3

European Union

2

Portugal

2

Spain

2

Japan

2

Hungary

2

Slovenia

2

Poland

1

Turkey

1

Russia

1

Brazil

1

Mexico

1

Korea, Republic of

1

Hong Kong

1

Canada

1

Cyprus

1

Australia

11. List of Victoza drug patents

VICTOZA's oppositions filed in EPO

VICTOZA litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US8114833 March, 2022 Terminated-Settled Novo Nordisk A/S Fresenius Kabi USA, LLC
US8114833 July, 2020 Terminated-Settled Novo Nordisk A/S Pfizer Inc.
US8114833 December, 2019 Terminated-Settled Novo Nordisk A/S Pfizer Inc.
US9265893 January, 2014 Decision Torben Stroem Hansen et al
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8114833 NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265893 NOVO NORDISK INC Injection button
Sep, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jun 17, 2022
Pediatric Exclusivity (PED) Dec 17, 2022

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 25 January, 2010

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of VICTOZA before it's patent expiration?
More Information on Dosage

VICTOZA family patents

8

United States

6

European Union

5

China

5

Denmark

3

Spain

3

Japan

3

Poland

2

Portugal

2

Russia

2

Brazil

2

Canada

2

Hungary

2

Slovenia

2

Australia

1

Germany

1

Turkey

1

Austria

1

Mexico

1

Korea, Republic of

1

Hong Kong

1

Cyprus

12. List of Lupkynis drug patents

LUPKYNIS litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US10286036 February, 2022 Terminated-Settled Aurinia Pharmaceuticals Inc. Sun Pharmaceutical Industries Ltd. et al.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10286036 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 22, 2026

Drugs and Companies using VOCLOSPORIN ingredient

NCE-1 date: 2025-01-22

Market Authorisation Date: 22 January, 2021

Treatment: Treatment of patients with active lupus nephritis

Dosage: CAPSULE;ORAL

More Information on Dosage

LUPKYNIS family patents

5

United States

2

Japan

1

Korea, Republic of

1

IB

1

Chile

1

Australia

1

Canada

1

Russia

1

South Africa

1

China

1

Brazil

1

European Union

13. List of Vascepa drug patents

VASCEPA's oppositions filed in EPO

VASCEPA litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US8642077 November, 2021 Terminated-Settled Amarin Pharmaceuticals Ireland Limited Hikma Pharmaceuticals USA Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642077 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 13, 2022

Drugs and Companies using ICOSAPENT ETHYL ingredient

Market Authorisation Date: 26 July, 2012

Treatment: Use of vascepa to reduce triglycerides in a mixed dyslipidemia adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy

Dosage: CAPSULE;ORAL

How can I launch a generic of VASCEPA before it's patent expiration?
More Information on Dosage

VASCEPA family patents

31

United States

3

Singapore

3

Russia

3

Hong Kong

3

European Union

2

Portugal

2

Spain

2

Croatia

2

New Zealand

2

Mexico

2

China

2

Lithuania

2

Slovenia

2

Hungary

2

Denmark

1

Malaysia

1

Brazil

1

Colombia

1

Norway

1

Philippines

1

Korea, Republic of

1

South Africa

1

Canada

1

Cyprus

1

Poland

1

Australia

14. List of Lumify drug patents

LUMIFY litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US8293742 November, 2021 Trial Instituted Eye Therapies, LLC et al. Slayback Pharma LLC et al.
US9259425 November, 2021 Terminated-Settled Eye Therapies, LLC Slayback Pharma LLC
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259425 BAUSCH AND LOMB INC Compositions and methods for eye whitening
Jul, 2030

(7 years from now)

US8293742 BAUSCH AND LOMB INC Preferential vasoconstriction compositions and methods of use
Jul, 2030

(7 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 22 December, 2017

Treatment: Relieves redness of the eye due to minor eye irritations

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LUMIFY before it's patent expiration?
More Information on Dosage

LUMIFY family patents

42

United States

4

Japan

4

Canada

4

European Union

2

Spain

1

Portugal

1

Slovenia

1

Korea, Republic of

1

Croatia

1

San Marino

1

Poland

1

Cyprus

1

Denmark

1

Russia

1

Mexico

1

Brazil

15. List of Pedmark drug patents

PEDMARK litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US10596190 October, 2021 Trial Instituted Oregon Health & Science University et al. Hope Medical Enterprises, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596190 FENNEC PHARMS INC Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
Jan, 2038

(14 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 20, 2025
Orphan Drug Exclusivity (ODE) Sep 20, 2029

Drugs and Companies using SODIUM THIOSULFATE ingredient

Market Authorisation Date: 20 September, 2022

Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administration of cisplatin

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of PEDMARK before it's patent expiration?
More Information on Dosage

PEDMARK family patents

5

United States

1

Japan

1

Korea, Republic of

1

Israel

1

Singapore

1

Australia

1

Russia

1

Canada

1

China

1

Brazil

1

European Union

16. List of Thiola Ec drug patents

THIOLA EC litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US11458104 October, 2021 Decision Mission Pharmacal Company
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458104 MISSION PHARMACAL CO NA
Nov, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
ODE* (ODE*) Jun 28, 2026

Drugs and Companies using TIOPRONIN ingredient

Market Authorisation Date: 28 June, 2019

Treatment: A method of treating cystinuria by orally administering tiopronin with food to prevent cystine stone formation in adults and pediatric patients with severe homozygous cystinuria

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of THIOLA EC before it's patent expiration?
More Information on Dosage

17. List of Levulan drug patents

LEVULAN litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US10357567 October, 2021 Terminated-Dismissed DUSA Pharmaceuticals, Inc. Biofrontera Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357567 DUSA Methods for photodynamic therapy
Jan, 2038

(14 years from now)

Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient

Market Authorisation Date: 03 December, 1999

Treatment: Treatment of actinic keratoses of upper extremities by photodynamic therapy

Dosage: SOLUTION;TOPICAL

More Information on Dosage

18. List of Austedo drug patents

AUSTEDO litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US8524733 September, 2021 Terminated-Denied Auspex Pharmaceuticals, Inc. Apotex Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8524733 TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 3, 2024
M (M) Jun 24, 2024
Pediatric Exclusivity (PED) Oct 3, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 03 April, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AUSTEDO before it's patent expiration?
More Information on Dosage

AUSTEDO family patents

18

United States

4

Spain

4

European Union

3

Hong Kong

3

Japan

2

China

2

Canada

2

Denmark

1

Portugal

1

Brazil

1

Croatia

1

New Zealand

1

Norway

1

Lithuania

1

Cyprus

1

Slovenia

1

Hungary

1

Poland

1

Australia

19. List of Austedo Xr drug patents

AUSTEDO XR litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US8524733 September, 2021 Terminated-Denied Auspex Pharmaceuticals, Inc. Apotex Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8524733 TEVA Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(8 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 17 February, 2023

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

AUSTEDO XR family patents

18

United States

4

Spain

4

European Union

3

Hong Kong

3

Japan

2

China

2

Canada

2

Denmark

1

Portugal

1

Brazil

1

Croatia

1

New Zealand

1

Norway

1

Lithuania

1

Cyprus

1

Slovenia

1

Hungary

1

Poland

1

Australia

20. List of Chantix drug patents

CHANTIX litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US6890927 June, 2021 Terminated-Settled Pfizer Inc. Apotex Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6890927 PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
May, 2022

(10 months ago)

Exclusivity Exclusivity Expiration
M (M) Feb 22, 2022
Pediatric Exclusivity (PED) Aug 22, 2022

Drugs and Companies using VARENICLINE TARTRATE ingredient

Market Authorisation Date: 10 May, 2006

Treatment: Aid to smoking cessation

Dosage: TABLET;ORAL

How can I launch a generic of CHANTIX before it's patent expiration?
More Information on Dosage

CHANTIX family patents

3

United States

2

Ecuador

1

Portugal

1

Germany

1

Malaysia

1

Panama

1

Guatemala

1

Spain

1

Brazil

1

Croatia

1

Costa Rica

1

IB

1

New Zealand

1

AP

1

Dominican Republic

1

Egypt

1

Estonia

1

Norway

1

Austria

1

Argentina

1

Mexico

1

Morocco

1

Peru

1

China

1

Taiwan, Province of China

1

Korea, Republic of

1

Hong Kong

1

EA

1

Tunisia

1

South Africa

1

Slovakia

1

Canada

1

Japan

1

Slovenia

1

Hungary

1

ME

1

Czech Republic

1

Ukraine

1

Iceland

1

Israel

1

OA

1

Yugoslavia

1

Georgia

1

Poland

1

Australia

1

Denmark

1

Bulgaria

1

European Union

21. List of Qelbree drug patents

QELBREE litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US11324753 February, 2021 Decision Supernus Pharmaceuticals, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11324753 SUPERNUS PHARMS Method of treatment of attention deficit/hyperactivity disorder (ADHD)
Sep, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 2, 2026
New Patient Population (NPP) Apr 29, 2025

Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient

NCE-1 date: 2025-04-02

Market Authorisation Date: 02 April, 2021

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

QELBREE family patents

7

United States

1

Canada

1

Spain

1

European Union

22. List of Tyvaso drug patents

TYVASO litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US10716793 January, 2021 Final Written Decision United Therapeutics Corporation Liquidia Technologies, Inc.
US9593066 March, 2020 Terminated-Denied United Therapeutics Corp. Liquidia Technologies, Inc.
US9604901 March, 2020 FWD Entered United Therapeutics Corp. Liquidia Technolgies, Inc.
US9339507 June, 2017 Terminated-Settled United Therapeutics Corp. Watson Laboratories, Inc.
US9358240 June, 2017 Terminated-Settled United Therapeutics Corp. Watson Laboratories, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9358240 UNITED THERAP Treprostinil administration by inhalation
May, 2028

(5 years from now)

US10716793 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(4 years from now)

US9339507 UNITED THERAP Treprostinil administration by inhalation
Mar, 2028

(4 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Mar 31, 2024

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 30 July, 2009

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device

Dosage: SOLUTION;INHALATION

How can I launch a generic of TYVASO before it's patent expiration?
More Information on Dosage

TYVASO family patents

23

United States

6

Japan

4

Korea, Republic of

3

China

3

European Union

2

Canada

2

Spain

23. List of Tyvaso Dpi drug patents

TYVASO DPI litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US10716793 January, 2021 Final Written Decision United Therapeutics Corporation Liquidia Technologies, Inc.
US9593066 March, 2020 Terminated-Denied United Therapeutics Corp. Liquidia Technologies, Inc.
US9604901 March, 2020 FWD Entered United Therapeutics Corp. Liquidia Technolgies, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10716793 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(4 years from now)

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 23 May, 2022

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device

Dosage: POWDER;INHALATION

More Information on Dosage

TYVASO DPI family patents

23

United States

6

Japan

4

Korea, Republic of

3

China

3

European Union

2

Canada

2

Spain

24. List of Cerdelga drug patents

CERDELGA's oppositions filed in EPO

CERDELGA litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US11458119 November, 2020 Decision Hanlan Liu et al.
US10888547 April, 2019 Decision Genzyme Corporation
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11458119 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Nov, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888547 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Jan, 2031

(7 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Market Authorisation Date: 19 August, 2014

Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 poor metabolizers with 84 mg once daily of eliglustat (equivalent to 100 mg of eliglustat tartrate); Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent to 100 mg of eliglustat tartrate twice per day)

Dosage: CAPSULE;ORAL

How can I launch a generic of CERDELGA before it's patent expiration?
More Information on Dosage

CERDELGA family patents

8

United States

6

European Union

5

China

5

Korea, Republic of

5

Japan

4

Portugal

4

Spain

4

Poland

3

Croatia

3

New Zealand

3

Argentina

3

Taiwan, Province of China

3

EA

3

Canada

3

Cyprus

3

Slovenia

3

Australia

3

RS

3

Denmark

2

Singapore

2

Dominican Republic

2

Peru

2

Hong Kong

2

Lithuania

2

Hungary

2

Israel

2

Chile

2

Ecuador

1

Malaysia

1

Guatemala

1

Brazil

1

Costa Rica

1

San Marino

1

Philippines

1

Mexico

1

Morocco

1

Tunisia

1

Nicaragua

1

ME

1

Ukraine

25. List of Cabenuva Kit drug patents

CABENUVA KIT's oppositions filed in EPO

CABENUVA KIT litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US11389447 October, 2020 Decision JANSSEN SCIENCES IRELAND UC
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389447 VIIV HLTHCARE Aqueous suspensions of TMC278
Jun, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026
New Patient Population (NPP) Mar 29, 2025
New Dosing Schedule (D) Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 2025-01-21

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

CABENUVA KIT family patents

5

United States

4

European Union

1

Portugal

1

Singapore

1

Uruguay

1

Spain

1

Jordan

1

Brazil

1

Croatia

1

New Zealand

1

AP

1

Argentina

1

Mexico

1

Peru

1

China

1

Taiwan, Province of China

1

Korea, Republic of

1

EA

1

Lithuania

1

Japan

1

Canada

1

Cyprus

1

Slovenia

1

Hungary

1

Ukraine

1

Israel

1

Poland

1

Chile

1

Australia

1

RS

1

Denmark

26. List of Lutathera drug patents

LUTATHERA litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US10596276 October, 2020 Terminated-Denied Advanced Accelerator Applications SA Evergreen Theragnostics, Inc.
US10596278 October, 2020 Terminated-Denied Advanced Accelerator Applications SA Evergreen Theragnostics, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596278 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(15 years from now)

US10596276 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 26, 2023
Orphan Drug Exclusivity (ODE) Jan 26, 2025

Drugs and Companies using LUTETIUM DOTATATE LU-177 ingredient

NCE-1 date: 2022-01-26

Market Authorisation Date: 26 January, 2018

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

LUTATHERA family patents

10

United States

4

Japan

4

European Union

3

IB

3

China

2

Australia

1

Taiwan, Province of China

1

Germany

1

Korea, Republic of

1

Israel

1

Colombia

1

Singapore

1

Canada

1

Argentina

1

Brazil

27. List of Elcys drug patents

ELCYS litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US10653719 September, 2020 Terminated-Denied Exela Pharma Sciences LLC Eton Pharmaceuticals, Inc.
US10583155 June, 2020 Terminated-Denied Exela Pharma Sciences, LLC Eton Pharmaceuticals Inc.
US10478453 May, 2020 Terminated-Denied Exela Pharma Sciences, LLC Eton Pharmaceuticals, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10653719 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10583155 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10478453 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 April, 2019

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of ELCYS before it's patent expiration?
More Information on Dosage

28. List of Nouress drug patents

NOURESS litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US10653719 September, 2020 Terminated-Denied Exela Pharma Sciences LLC Eton Pharmaceuticals, Inc.
US10583155 June, 2020 Terminated-Denied Exela Pharma Sciences, LLC Eton Pharmaceuticals Inc.
US10478453 May, 2020 Terminated-Denied Exela Pharma Sciences, LLC Eton Pharmaceuticals, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10653719 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10583155 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10478453 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 December, 2019

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

29. List of Entresto drug patents

ENTRESTO's oppositions filed in EPO

ENTRESTO litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US8101659 August, 2020 Terminated-Denied Novartis Pharmaceuticals Corporation Biocon Pharma Limited
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101659 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jan, 2025

(1 year, 9 months from now)

Exclusivity Exclusivity Expiration
M (M) Feb 16, 2024
Pediatric Exclusivity (PED) Apr 1, 2023

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 07 July, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ENTRESTO before it's patent expiration?
More Information on Dosage

ENTRESTO family patents

7

United States

3

Brazil

2

Norway

2

China

2

Korea, Republic of

2

Japan

2

European Union

1

Portugal

1

Germany

1

Russia

1

Spain

1

Colombia

1

New Zealand

1

Mexico

1

Austria

1

Belgium

1

South Africa

1

Canada

1

Hungary

1

Slovenia

1

Luxembourg

1

Israel

1

Poland

1

Australia

1

Ecuador

1

Denmark

1

Netherlands

30. List of Naproxen Sodium drug patents

NAPROXEN SODIUM's oppositions filed in EPO

NAPROXEN SODIUM litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US11090280 July, 2020 Decision PATHEON SOFTGELS INC
US9693978 January, 2018 Terminated-Denied Patheon Softgels Inc. Catalent Pharma Solutions, Inc.
US9693979 January, 2018 Terminated-Denied Patheon Softgels Inc. Catalent Pharma Solutions, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9693979 BIONPHARMA INC Liquid dosage forms of sodium naproxen
Mar, 2026

(2 years from now)

US11090280 BIONPHARMA INC Liquid dosage forms of sodium naproxen
Mar, 2026

(2 years from now)

US9693978 BIONPHARMA INC Solvent system for enhancing the solubility of pharmaceutical agents
Mar, 2026

(2 years from now)

Drugs and Companies using NAPROXEN SODIUM ingredient

Market Authorisation Date: 17 February, 2006

Treatment: Temporary relief of minor aches and pains; Temporary reduction of fever

Dosage: CAPSULE;ORAL

How can I launch a generic of NAPROXEN SODIUM before it's patent expiration?
More Information on Dosage

NAPROXEN SODIUM family patents

9

United States

2

China

2

European Union

1

Portugal

1

Hungary

1

Slovenia

1

Poland

1

Denmark

1

Mexico

1

Lithuania

1

Spain

1

Canada

1

Cyprus

31. List of Janumet drug patents

JANUMET's oppositions filed in EPO

JANUMET litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US7326708 June, 2020 FWD Entered Merck Sharp & Dohme Corp. Sun Pharmaceutical Industries Ltd.
US7326708 June, 2020 FWD Entered Merck Sharp & Dohme Corp. Dr. Reddy's Laboratories, Inc.
US7326708 June, 2020 Terminated-Settled Merck Sharp & Dohme Corp. Teva Pharmaceuticals USA, Inc.
US7326708 October, 2019 FWD Entered Merck Sharp & Dohme Corp. Mylan Pharmaceuticals, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
M (M) Dec 4, 2023
Pediatric Exclusivity (PED) Jun 4, 2024

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 30 March, 2007

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor

Dosage: TABLET;ORAL

How can I launch a generic of JANUMET before it's patent expiration?
More Information on Dosage

JANUMET family patents

3

United States

2

Argentina

2

Korea, Republic of

1

Portugal

1

Germany

1

Malaysia

1

Spain

1

Jordan

1

Brazil

1

Croatia

1

Costa Rica

1

Colombia

1

New Zealand

1

Dominican Republic

1

Norway

1

Austria

1

Mexico

1

Morocco

1

Peru

1

China

1

Taiwan, Province of China

1

Hong Kong

1

Tunisia

1

EA

1

South Africa

1

Canada

1

Japan

1

Cyprus

1

Slovenia

1

ME

1

Yugoslavia

1

Ukraine

1

Israel

1

Iceland

1

Georgia

1

Poland

1

Australia

1

Ecuador

1

Denmark

1

European Union

32. List of Janumet Xr drug patents

JANUMET XR's oppositions filed in EPO

JANUMET XR litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US7326708 June, 2020 FWD Entered Merck Sharp & Dohme Corp. Sun Pharmaceutical Industries Ltd.
US7326708 June, 2020 FWD Entered Merck Sharp & Dohme Corp. Dr. Reddy's Laboratories, Inc.
US7326708 June, 2020 Terminated-Settled Merck Sharp & Dohme Corp. Teva Pharmaceuticals USA, Inc.
US7326708 October, 2019 FWD Entered Merck Sharp & Dohme Corp. Mylan Pharmaceuticals, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
M (M) Dec 4, 2023
Pediatric Exclusivity (PED) Jun 4, 2024

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 02 February, 2012

Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JANUMET XR before it's patent expiration?
More Information on Dosage

JANUMET XR family patents

3

United States

2

Argentina

2

Korea, Republic of

1

Portugal

1

Germany

1

Malaysia

1

Spain

1

Jordan

1

Brazil

1

Croatia

1

Costa Rica

1

Colombia

1

New Zealand

1

Dominican Republic

1

Norway

1

Austria

1

Mexico

1

Morocco

1

Peru

1

China

1

Taiwan, Province of China

1

Hong Kong

1

Tunisia

1

EA

1

South Africa

1

Canada

1

Japan

1

Cyprus

1

Slovenia

1

ME

1

Yugoslavia

1

Ukraine

1

Israel

1

Iceland

1

Georgia

1

Poland

1

Australia

1

Ecuador

1

Denmark

1

European Union

33. List of Januvia drug patents

JANUVIA's oppositions filed in EPO

JANUVIA litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US7326708 June, 2020 FWD Entered Merck Sharp & Dohme Corp. Sun Pharmaceutical Industries Ltd.
US7326708 June, 2020 FWD Entered Merck Sharp & Dohme Corp. Dr. Reddy's Laboratories, Inc.
US7326708 June, 2020 Terminated-Settled Merck Sharp & Dohme Corp. Teva Pharmaceuticals USA, Inc.
US7326708 October, 2019 FWD Entered Merck Sharp & Dohme Corp. Mylan Pharmaceuticals, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
M (M) Dec 4, 2023
Pediatric Exclusivity (PED) Feb 12, 2023

Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 16 October, 2006

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor

Dosage: TABLET;ORAL

How can I launch a generic of JANUVIA before it's patent expiration?
More Information on Dosage

JANUVIA family patents

3

United States

2

Argentina

2

Korea, Republic of

1

Portugal

1

Germany

1

Malaysia

1

Spain

1

Jordan

1

Brazil

1

Croatia

1

Costa Rica

1

Colombia

1

New Zealand

1

Dominican Republic

1

Norway

1

Austria

1

Mexico

1

Morocco

1

Peru

1

China

1

Taiwan, Province of China

1

Hong Kong

1

Tunisia

1

EA

1

South Africa

1

Canada

1

Japan

1

Cyprus

1

Slovenia

1

ME

1

Yugoslavia

1

Ukraine

1

Israel

1

Iceland

1

Georgia

1

Poland

1

Australia

1

Ecuador

1

Denmark

1

European Union

34. List of Juvisync drug patents

JUVISYNC's oppositions filed in EPO

JUVISYNC litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US7326708 June, 2020 FWD Entered Merck Sharp & Dohme Corp. Sun Pharmaceutical Industries Ltd.
US7326708 June, 2020 FWD Entered Merck Sharp & Dohme Corp. Dr. Reddy's Laboratories, Inc.
US7326708 June, 2020 Terminated-Settled Merck Sharp & Dohme Corp. Teva Pharmaceuticals USA, Inc.
US7326708 October, 2019 FWD Entered Merck Sharp & Dohme Corp. Mylan Pharmaceuticals, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Apr, 2026

(3 years from now)

Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate

Dosage: TABLET;ORAL

More Information on Dosage

JUVISYNC family patents

3

United States

2

Argentina

2

Korea, Republic of

1

Portugal

1

Germany

1

Malaysia

1

Spain

1

Jordan

1

Brazil

1

Croatia

1

Costa Rica

1

Colombia

1

New Zealand

1

Dominican Republic

1

Norway

1

Austria

1

Mexico

1

Morocco

1

Peru

1

China

1

Taiwan, Province of China

1

Hong Kong

1

Tunisia

1

EA

1

South Africa

1

Canada

1

Japan

1

Cyprus

1

Slovenia

1

ME

1

Yugoslavia

1

Ukraine

1

Israel

1

Iceland

1

Georgia

1

Poland

1

Australia

1

Ecuador

1

Denmark

1

European Union

35. List of Steglujan drug patents

STEGLUJAN's oppositions filed in EPO

STEGLUJAN litigations

Patent Proceeding Filing Date Status Respondent Petitioner
US7326708 June, 2020 FWD Entered Merck Sharp & Dohme Corp. Sun Pharmaceutical Industries Ltd.
US7326708 June, 2020 FWD Entered Merck Sharp & Dohme Corp. Dr. Reddy's Laboratories, Inc.
US7326708 June, 2020 Terminated-Settled Merck Sharp & Dohme Corp. Teva Pharmaceuticals USA, Inc.
US7326708 October, 2019 FWD Entered Merck Sharp & Dohme Corp. Mylan Pharmaceuticals, Inc.
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
M (M) Sep 17, 2024

Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage

STEGLUJAN family patents

3

United States